Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer

Tumor Biology

Volumn 25, Issue 3, 2004, Pages 149-156

  Kurlender, Lisa ^a,b   Yousef, George M ^b,c   Memari, Nader ^a,b   Robb, John Desmond ^b,c   Michael, Iacovos P ^a,b   Borgoño, Carla ^a,b   Katsaros, Dionyssios ^d   Stephan, Carsten ^e   Jung, Klaus ^e   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d UNIVERSITY OF TURIN   (Italy)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alternative splicing; Cancer biomarkers; Differential expression; Kallikreins; KLK5; Ovarian cancer; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; KALLIKREIN 5; MESSENGER RNA; STEROID HORMONE; TUMOR MARKER; UNCLASSIFIED DRUG; KALLIKREIN 5, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; MALE; MAMMARY GLAND; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN VARIANT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA TRANSCRIPTION; SALIVARY GLAND; SKIN; TISSUE DISTRIBUTION; TISSUE LEVEL; UTERINE CERVIX; BIOSYNTHESIS; CELL CULTURE; GENE EXPRESSION PROFILING; GENETICS; MOLECULAR GENETICS; OVARY TUMOR; PATHOLOGY; PROSTATE TUMOR; RNA SPLICING;

BASE SEQUENCE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KALLIKREINS; MALE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICE SITES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 4644307382     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079147     Document Type: Article

References (31)

1. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204.
2. Yousef GM, Diamandis EP: The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation, J Biol Chem 1999;274:37511-37516.
3. Brattsand M, Egelrud T: Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 1999;274:30033-30040.
4. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, Diamandis EP: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001;84:643-650.
5. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP: Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem 2002;48:1241-1250.
6. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP: Downregulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002;51:126-132.
7. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP: Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002;60:714-718.
8. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgono CA, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP: Human kallikrein 5 (hK5): A potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-3965.
9. Horowitz DS, Krainer AR: Mechanisms for selecting 5′ splice sites in mammalian pre-mRNA splicing. Trends Genet 1994;10:100-106.
10. Baffa R, Moreno JG, Monne M, Veronese ML, Gomella LG: A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostate tissue. Urology 1996;47:795-800.
11. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA: Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 1997;74:630-636.
12. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402.
13. Brett D, Pospisil H, Valcarcel J, Reich J, Bork P: Alternative splicing and genome complexity. Nat Genet 2002;30:29-30.
14. Yousef GM, Diamandis EP: Human kallikreins: Common structural features, sequence analysis and evolution. Curr Genom 2003;4:147-165.
15. Chang A, Yousef GM, Jung K, Rajpert-De Meyts E, Diamandis EP: Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: Differential expression in the human testis and testicular cancer. Anticancer Res 2001;21:3147-3152.
16. Lewin B: Genes VI. New York, Oxford University Press, 1997.
17. Erbil C, Niessing J: The primary structure of the duck alpha D-globin gene: An unusual 5′ splice junction sequence. EMBO J 1983;2:1339-1343.
18. Wieringa B, Meyer F, Reiser J, Weissmann C: Unusual splice sites revealed by mutagenic inactivation of an authentic splice site of the rabbit beta-globin gene. Nature 1983;301:38-43.
19. King CR, Piatigorsky J: Alternative RNA splicing of the murine alpha A-crystallin gene: Protein-coding information within an intron. Cell 1983;32:707-712.
20. Thanaraj TA, Clark F: Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res 2001;29:2581-2593.
21. Mironov AA, Fickett JW, Gelfand MS: Frequent alternative splicing of human genes. Genome Res 1999;9:1288-1293.
22. Hake LE, Richter JD: Translational regulation of maternal mRNA. Biochim Biophys Acta 1997;1332:M31-M38.
23. Curtis D, Lehmann R, Zamore PD: Translational regulation in development. Cell 1995;81:171-178.
24. Wickens M, Kimble J, Strickland S: Translational control of developmental decisions; in Hershey JWB, Mathews MB, Sonenberg N (eds): Translational Control. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1996, pp 411-450.
25. van der Velden AW, Thomas AA: The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 1999;31:87-106.
26. Arrick BA, Grendell RL, Griffin LA: Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol Cell Biol 1994;14:619-628.
27. Blasiak J, Przybylowska K, Czechowska A, Zadrozny M, Pertynski T, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J: Analysis of the G/C polymorphism in the 5′-untranslated region of the RAD51 gene in breast cancer. Acta Biochim Pol 2003;50:249-253.
28. Diamandis EP: Prostate-specific antigen - Its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-316.
29. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA: Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003;107:323-329.
30. Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G: The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol 2003;20:255-263.
31. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA: Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003;9:1710-1720.